Sirolimus albumin bound

Drug Profile

Sirolimus albumin bound

Alternative Names: ABI-009; Nab-rapamycin; Nab-sirolimus; Rapamycin albumin bound

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Abraxis BioScience
  • Developer AADi; Celgene Corporation
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Perivascular epithelioid cell tumours
  • Phase I/II Bladder cancer
  • Research Pulmonary arterial hypertension
  • No development reported Solid tumours

Most Recent Events

  • 15 Nov 2016 National Cancer Institute and Children's Oncology Group plan a phase I trial in Solid tumours (Combination therapy, In infants, In children, In adolescents, In adults, Recurrent, Monotherapy, Second-line therapy or greater) in USA (NCT02975882)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
  • 06 May 2016 Efficacy, safety and pharmacokinetics data from a phase I/II trial in Bladder cancer presented at the Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top